Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35)

Virology

Volumn 226, Issue 1, 1996, Pages 13-21

  Zhou, Jintao ^a   Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS GLYCOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; NORMAL HUMAN; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030560950     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1996.0623     Document Type: Article

References (63)

1. Banapour, B., Sernatinger, J., and Levy, J.A. (1986). The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 152, 268-271.
2. Brekke, O. H., Michaelsen, T. E., and Sandlie, I. (1995). The structural requirements for complement activation by IgG: Does it hinge on the hinge? Immunol. Today 16, 85-90.
3. Cornacoff, J. B., Herbert, L. A., Smead, W. L., Van Aman, M. E., Birmingham, D. J., and Waxman, F. J. (1983). Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest. 71, 236-247.
4. Delibrias, C.-C., Mouhoub, A., Fischer, E., and Kazatchkine, M. D. (1994). CR1 (CD35) and CF2 (CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur. J. Immunol. 24, 2784-2788.
5. Ebenbichler, C. F., Thielens, N. M., Vornhagen, R., Marschang, P., Arlaud, G. J., and Dierich, M. P. (1991). Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174, 1417-1424.
6. Fearon, D. T. (1978). Regulation by membrane sialic acid of B1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75, 1971-1975.
7. Fearon, D. T. (1980). Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte and monocyte. J. Exp. Med. 152, 20-30.
8. Fiscus, S.A., Folds, J. D., and van der Horst, C. M. (1993). Infectious immune complexes in HIV-1 infected patients. Viral Immunol. 6, 135-141.
9. Graham, B. S., Gorse, G. J., Schwartz, D.H., Keefer, M.C., McElrath, M.J., Matthews, T.J., Wright, P. F., Belshe, R. B., Clements, M. L., Dolin, R., Corey, L., Bolognesi, D. P., Stablein, D. M., Esterlitz, J. R., Hu, S-L., Smith, G. E., and the National Institutes of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. (1994). Determinants of antibody response after recombinant gp160 boosting in vaccinianaive volunteers primed with gp160-recombinant vaccinia virus. J. Infect. Dis. 170, 782-786.
10. Graham, B. S., Matthews, T. J., Belshe, R. B., Clements, M. L., Dolin, R., Wright, P. F., Gorse, G. J., Schwartz, D. H., Keefer, M. C., Bolognesi, D. P., Corey, L., Stablein, D. M., Esterlitz, J. R., Hu, S.-L., Smith, G. E., Fast, P. E., Koff, W. C., and the NIAID AIDS Vaccine Clinical Trials Network. (1993). Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167, 533-537.
11. Harada, S., Yoshiyama, H., and Yamamoto, N. (1985). Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systems. J. Clin. Microbiol. 22, 908-911.
12. Heath, S. L., Tew, J. G., Tew, J. G., Szakal, A. K., and Burton, G. F. (1995). Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744.
13. Herbert, L. A., and Cosio, F. G. (1987). The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int. 31, 877-885.
14. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
15. Inada, Y., Lange, M., McKinley, G. F., Sonnabend, J.A., Fonville, T. W., Kanemitsu, T., Tanaka, M., and Clark, W. S. (1986). Hematologic correlates and the role of erythrocyte CR1 (C3b receptors) in the development of AIDS. AIDS Res. 2, 235-247.
16. Jacob, J., Kelsoe, G., Rajewsky, K., and Weiss, U. (1991). Intraclonal generation of antibody mutants in germinal centres. Nature 354, 389-392.
17. Joling, P., Bakker, L. J., Van Strijp, J. A. G., Meerloo, T., de Graaf, L., Dekker, M. E. M., Goudsmit, J., Verhoef, J., and Schuurman, H.-J. (1993). Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J. Immunol. 150, 1065-1073.
18. Jouvin, M.-H., Rozenbaum, W., Russo, R., and Kazatchkine, M. D. (1987). Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1, 89-94.
19. Khalife, J., Guy, B., Capron, M., Kieny, M-P., Ameisen, J-C., Montagnier, L., Lecocq, J-P., and Capron, A. (1988). Isotypic restriction of antibody response to human immunodeficiency virus. AIDS Res. Hum. Retroviruses 4, 3-9.
20. Klasse, P. J., and Blomberg, J. (1987). Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG. J. Infect. Dis. 156, 1026-1030.
21. Klickstein, L. B., Bartlow, T. J., Miletic, V., Radson, L. D., Smith, J. S., and Fearon, D. T. (1988). Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168, 1699-1710.
22. Kobayashi, K., Takeda, A., Green, S., Tuazon, C. U., and Ennis, F. A. (1993). Direct detection of infectious human immunodeficiency virus type 1 (HIV-1) immune complexes in the sera of HIV-1-infected persons. J. Infect. Dis. 168, 729-732.
23. Marschang, P., Gurtler, L., Totsch, M., Thielens, N.M., Arlaud, G. J., Hittmair, A., Katinger, H., and Dierich, M. P. (1993). HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS 7, 903-910.
24. Marschang, P., Sodroski, J., Wurzner, R., and Dierich, M. P. (1995). Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25, 285-290.
25. Montefiori, D. C. (1996). Role of complement in HIV and SIV pathogenesis and immunity. In "Symposium in Immunology V: Antiviral Immunity" (M. M. Eible, C. Huber, H. H. Peter, U. Wahn, Eds.), pp. 31-53. Springer-Verlag, Heidelberg, Germany.
26. Montefiori, D. C., Cornell, R. J., Zhou, J. Y., Zhou, J. T., Hirsch, V. M., and Johnson, P. R. (1994). Complement control proteins, CD46, CD55 and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205, 82-92.
27. Montefiori, D. C., Graham, B. S., Kliks, S., Wright, P. F., and the NIAID AIDS Vaccine Clinical Trials Nework. (1992a). Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Immunol. 12, 429-439.
28. Montefiori, D. C., Graham, B. S., Zhou, J. Y., Zhou, J. T., and Ahearn, J. M. (1994). Binding of human immunodeficiency virus type 1 to the C3b/ C4b receptor, CR1 (CD35), and red blood cells in the presence of envelope-specific antibodies and complement. J. Infect. Dis. 170, 429-432.
29. Montefiori, D. C., Graham, B. S., Zhou, J. T., Zhou, J. Y., Bucco, R., Cavacini, L.A., Posner, M. R., and the NIH AIDS Vaccine Clinical Trials Network. (1993a). V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding region of gp120. J. Clin. Invest. 92, 840-847.
30. Montefiori, D. C., Pantaleo, G., Fink, L. M., Zhou, J. T., Zhou, J. Y., Bilska, M., Miralles, G. D., and Fauci, A. S. (1996). Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long term non-progressors. J. Infect. Dis. 173, 60-67.
31. Montefiori, D. C., Robinson, W. E., Jr., Schuffman, S. S., and Mitchell, W. M. (1988). Evaluation of antiviral drugs and neutralizing antibodies against human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26, 231-235.
32. Montefiori, D. C., Stewart, K., Ahearn, J. M., Zhou, J. T., and Zhou, J. Y. (1993b). Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J. Virol. 67, 2699-2706.
33. Montefiori, D. C., Zhou, J., and Shaff, D.I. (1992b). CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody. Clin. Exp. Med. 90, 383-389.
34. Morrow, W. J. W., Wharton, M., Stricker, R. B., and Levy, J. A. (1986). Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin. Immunol. Immunopathol. 40, 515-524.
35. Muller-Eberhard, H. J. (1988). Molecular organization and function of the complement system. Annu. Rev. Biochem. 57, 321-347.
36. Nelson, R. A. (1953). The immune adherence phenomenon: an immunologically specific reaction between micro-organisms and erythrocytes leading to enhanced phagocytosis. Science 118, 733-737.
37. Pantaleo, G., Graziosi, C., Demarest, J. F., Cohen, O. J., Vaccarezza, M., Gantt, K., Muro-Cacho, C., and Fauci, A. S. (1994). Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol. Rev. 140, 105-130.
38. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., and Ho, D. D. (1996). HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586.
39. Perricone, R., Fontana, L., De Carolis, C., Carini, C., Sirianni, M. C., and Aiuti, F. (1987). Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphadenopathy syndrome (LAS). Clin. Exp. Immunol. 70, 500-507.
40. Pinter, C., Siccardi, A. G., Longhi, R., and Clivio, A. (1995). Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 11, 577-588.
41. Reynes, M., Aubert, J. P., Cohen, J. H. M., Audouin, J., Tricottet, V., Diebold, J., and Kazatchkine, M. D. (1985). Human follicular dendritic cells express CR1, CR2 and CR3 complement receptor antigens. J. Immunol. 135, 2687-2697.
42. Robinson, W. E., Gorny, M.W., Xu, J.-Y., Mitchell, W. M., and Zolla-Pazner, S. (1991). Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 65, 4169-4176.
43. Robinson, W. E., Kawamura, T., Lake, D., Masuho, Y., Mitchell, W. M., and Hersh, E. M. (1990). Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1)glycoprotein gp41 enhance HIV-1 infection in vitro. J. Virol. 64, 5301-5305.
44. Ross, G., and Medof, M. E. (1985). Membrane complement receptors specific for bound fragments of C3. Adv. Immunol. 37, 217-267.
45. Rosse, W. F. (1987). The spleen as a filter. N. Engl. J. Med. 317, 704-706.
46. Saifuddin, M., Parker, C. J., Peeples, M. E., Gorny, M. K., Zolla-Pazner, S., Ghassemi, M., Rooney, I. A., Atkinson, J. P., and Spear, G. T. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182, 501-509.
47. Schifferli, J. A., Ng, Y. C., Estreicher, J., and Walport, M. J. (1988). The clearance of tetanus toxoid-anti tetanus toxoid immune complexes from the circulation of humans: Complement-and erythrocyte CR1-dependent mechanisms. J. Immunol. 141, 899-904.
48. Schmitz, J., van Lunzen, J., Tenner-Racz, K., Grosschupff, G., Racz, P., Schmitz, H., Dietrich, M., and Hufert, F. T. (1994). Follicular dendritic cells retain HIV-1 particles on their plasma membrane but are not productively infected in asymptomatic patients with follicular hyperplasia. J. Immunol. 153, 1352-1359.
49. Schumaker, V. N., Calcott, M. A., Spiegelberg, H. L., and Muller-Eberhard, H. J. (1976). Ultracentrifuge studies of the binding of IgG of different subclasses to the C1q subunit of the first component of complement. Biochemistry 15, 5175-5181.
50. Senaldi, G., Peakman, M., McManus, T., Davies, E. T., Tee, D. E. H., and Vergani, D. (1990). Activation of the complement system in human immunodeficiency virus infection: Relevance of the classical pathway to pathogenesis and disease severity. J. Infect. Dis. 162, 1227-1232.
51. Soelder, B. M., Schultz, T. F., Hengster, P., Lower, J., Larcher, C., Bitterlich, G., Kurth, R., Wachter, H., and Dierich, M. P. (1989). HIV and HIV-infected cells differentially activate the human complement system independently of antibody. Immunol. Lett. 22, 135-146.
52. Spiegelberg, H. L. (1974). Biological activities of immunoglobulins of different classes and subclasses. Adv. Immunol. 19, 259-272.
53. Stoiber, H., Pinter, C., Siccardi, A. G., Clivio, A., and Dierich, M. P. (1996). Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J. Exp. Med. 183, 307-310.
54. Sundquist, V-A., Linde, A., Kurth, R., Werner, A., Helm, E. B., Popovic, M., Gallo, R. C., and Wahren, B. (1986). Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J. Infect. Dis. 153, 970-973.
55. Susal, C., Kirschfink, M., Kropelin, M., Daniel, V., and Opelz, G. (1994). Complement activation by recombinant HIV-1 glycoprotein gp120. J. Immunol. 152, 6028-6034.
56. Tausk, F. A., McCutchan, J. A., Spechko, P., Schreiber, R. D., and Gigli, I. (1986). Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J. Clin. Invest. 78, 977-982.
57. Tew, J. G., and Mandel, T. E. (1978). The maintenance and regulation of serum antibody levels: Evidence indicating a role for antigen retained in lymphoid follicles. J. Immunol. 120, 1063-1069.
58. Thieblemont, N., Haeffner-Cavaillon, N., Ledur, A., L'age-Stehr, J., Ziegler-Heitbrock, H. W. L., and Kazatchkine, M. D. (1993a). CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin. Exp. Immunol. 92, 106-113.
59. Thieblemont, N., Haeffner-Cavaillon, N., Weiss, L., Maillet, F., and Kazatchkine, M. D. (1993b). Complement activation by gp160 glycoprotein of HIV-1. AIDS Res. Hum. Retroviruses 9, 229-233.
60. Thielens, N. M., Bally, I. M., Ebenbichler, C. F., Dierich, M. P., and Arlaud, G. J. (1993). Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J. Immunol. 151, 6583-6592.
61. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B., Saag, M. S., and Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
62. Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Jr., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeld, M. L., and Fearon, D. T. (1990). Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249, 146-151.
63. Wilson, J. G., Tedder, T. F., and Fearon, D.T. (1983). Characterization of human T lymphocytes that express the C3b receptor. J. Immunol. 131, 684-689.